BioInvent: Fair Value Adjusted for Rights Issue Terms

Summary by AI BETAClose X

Redeye published a Research Note stating it has adjusted its fair value estimate for BioInvent to reflect the terms of a forthcoming rights issue and attached the update titled 'BioInvent: Fair Value Adjusted for Rights Issue Terms.' The press release contains no revenue, profit, cash or debt figures; the valuation revision and rights issue terms may materially affect share dilution and market value, so investors should review Redeye’s attached note for the detailed quantitative impact.

Disclaimer*

UK 100

Latest directors dealings